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Acute wheeze is a common problem in young children. Population studies have shown that approximately one in three children has at least one episode of wheezing 
by 3 years of age, and the overall prevalence of wheeze is about 
50% at the age of 6 years [1-3]. Many cohort studies have been 
done to study the prevalence of wheeze in children. These studies 
show a great degree of variation and indicate that up to 10–80.3% 
of infants suffer at least one episode of wheezing during their 
1st year of life, while 8–43.1% have three or more episodes, with 
lower prevalence rates in developed countries [4]. One-half of 
children who wheeze early in life cease to do so by 6 years of age. 
However, there are a few patients in which the symptoms continue. 
Appropriate identification of children at risk of developing asthma 
or future wheezing episodes and apt preventive medications can 
improve long-term outcomes, but the possibility to identify these 
children at preschool age remains limited [5].
Inhaled salbutamol is the most commonly used drugs for the 
management of acute wheeze. It can be given both by nebulizer 
and a metered dose inhaler. In cases of severe acute wheeze, 
continuous/repeated salbutamol nebulizations are sometimes 
required. The efficacy of repeated/continuous salbutamol 
nebulizations as compared to intermittent therapy has been 
established in children with severe acute wheeze [6]. The side 
effect such as hypokalemia, tachycardia, and possibility of cardiac 
arrhythmias after repeated/continuous salbutamol nebulizations 
is not well known. In general, these side effects are more marked 
when salbutamol is administered by oral or parenteral route [7].
A few studies have shown that nebulized salbutamol can 
induce symptomatic hypokalemia in adults and children at 
conventional doses [8-10]. Singhi et al. studied 46 children, of 
which hypokalemia (serum potassium<3.5 mEq/L) occurred 
in one-third of patients treated with three doses of salbutamol 
nebulizations, particularly in those who received prior treatment 
with oral salbutamol. The monitoring of serum potassium 
concentration was advised in such patients [11,12].
It is of clinical importance to explore this further since 
children with severe acute wheeze usually receive large doses 
of β2 agonists and also theophylline and steroid, which could 
further activate cAMP-dependent Na+/K+ ATPase and this might 
accentuate symptomatic hypokalemia [13]. Furthermore, children 
with an exacerbation of asthma often have viral infections that may 
cause vomiting and diarrhea, which can augment hypokalemia.
Beta2-agonists are also known to induce tachycardia and 
other electrocardiogram (ECG) changes. It has been seen that 
salbutamol can prolong QTc by 23±15 ms after three repeated 
nebulizations [14]. Another study demonstrated that a large 
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therapeutic single dose (600 mcg) of inhaled salbutamol has 
a profound effect on cardiovascular autonomic regulation in 
prepubertal children with bronchial asthma. It was seen that 
this dose of inhaled salbutamol markedly decreased beat to beat 
variability of RR interval [15]. However, the dose of inhaled 
salbutamol which can cause life-threatening arrhythmias, 
especially during repeated nebulizations and above which one 
should do careful cardiac monitoring is not yet established.
Keeping in view the requirement of repeated salbutamol 
nebulizations in a child with acute wheeze, this study was done to 
find whether there are any significant changes in serum potassium 
levels during this time so that recommendations regarding routine 
potassium supplementation (orally or intravenous) during this 
period can be made in future. Furthermore, secondary objective 
of the study was whether there are any significant ECG changes 
in the form of QTc prolongation during this therapy.
METHODS
This cross-sectional observational study was conducted from 
January 2015 to September 2016 at pediatric ward of a tertiary 
care teaching hospital. The study was cleared by the institutional 
ethics committee. A total of 41 children aged from 6 months to 
12 years requiring repeated nebulizations (three or more) with 
salbutamol within a period of 1–2 h for acute wheeze were 
enrolled. Exclusion criteria were children with high risk for 
hypokalemia such as acute gastroenteritis, diabetic ketoacidosis, 
and Cushing syndrome and those on drugs such as diuretics, 
systemic steroids, and systemic β2-agonists.
Pediatric asthma score (PAS) was performed to assess the 
severity of wheeze and to decide management. Baseline vital 
parameters (heart rate, respiratory rate, and spO2) were recorded. 
Children who had PAS of >3 were considered in this study as they 
would require repeated salbutamol nebulizations. The sample 
was collected for baseline serum potassium levels at the onset 
of nebulizations and dispatched to hospital laboratory. Then, the 
study population was given repeated salbutamol nebulizations at 
a dose of 0.15 mg/kg/nebulization as often as every 15–20 min as 
required depending on the clinical response (for maximum up to 
4 h). Another blood sample for serum potassium level was taken 
at the end of repeated nebulizations within 1–2 h (before starting 
intermittent nebulizations).
Number and duration of repeated nebulizations were 
documented, and post-nebulizations vital parameters such as 
heart rate, respiratory rate, spO2, and PAS were also documented. 
A 12-lead ECG was taken at the end of 1st h for all children and 
then at 3 h if the child continued to receive repeated nebulizations 
until then. We studied QTc on each ECG and a corrected Q-T 
interval was calculated using Fridericia’s formula (observed QT 
interval in lead II divided by cube root of R-R interval in second). 
Statistical package used for the analysis was SPSS 23.
RESULTS
A total of 41 children aged from 6 months to 12 years presenting 
with acute wheeze and fitting into eligibility criteria were analyzed 
in the present study. The mean age of the study population was 
3.1 years. Of the 41 cases, 58.5% were male and 41.5% were 
females.
Baseline clinical parameters of the children presenting with 
acute wheeze are shown in Table 1. The study population required 
3–6 repeated nebulizations over 90–230 min on acute presentation 
before they were treated with intermittent nebulizations. The 
mean number of repeated nebulizations required was 3.9±1.0 
over a mean period of 140.9±47.9 (min). Clinical parameters at 
the end of repeated salbutamol nebulizations are also shown in 
Table 1.
The difference in clinical parameters at the onset and at 
the end of repeated salbutamol nebulizations is depicted in 
Table 2. The mean difference in heart rate pre- and post-repeated 
Table 1: Clinical parameters of the patients
Characteristic Baseline clinical parameters Clinical parameters at the end of repeated salbutamol nebulizations
Mean±SD (range) Mean±SD (range)
Heart rate (beats per min) 122.7±10.4 9 (102–144) 138.3±13.2 (114–168)
Respiratory rate (per min) 47.9±15.9 (24–75) 40.2±13.4 (20.0–65.0)
PAS 6.7±2.6 (4–15) 4.9±1.8 (3.0–9.0)
PAS: Pediatric asthma score
Table 2: Difference in clinical parameters at the onset and at the end of repeated salbutamol nebulizations
Parameters Mean difference SD 95% Confidence interval of the difference p value
Lower Upper
Pair 1
Heart rate difference −15.6 5.2 −17.2 −13.9 <0.0001
Pair 2
Respiratory rate difference 7.7 4.0 6.5 9.0 <0.0001
Pair 3
PAS difference 3.6 1.1 3.2 3.9 <0.0001
PAS: Pediatric asthma score
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salbutamol nebulizations was −15.6±5.2 (negative value because 
post nebulization figure is higher, i.e., there is a significant rise 
in heart rate post-repeated nebulizations) (p<0.05, paired t-test). 
The mean change in respiratory rate was 7.7±4.0 (value is 
positive because post nebulization figure is lower; i.e., there is 
a significant fall in respiratory rate post-repeated nebulizations) 
(p<0.05, paired t-test). The mean change in PAS before and after 
repeated salbutamol nebulizations was 3.6±1.1 (p<0.05, paired 
t-test), i.e., there was a significant fall in the severity of wheeze 
post-repeated salbutamol nebulizations.
The mean serum potassium concentration before and after 
repeated salbutamol nebulizations was 4.3±0.5 and 4.0±0.5, 
respectively. The mean fall was 0.3±0.4 (p<0.05, paired test). 
The fall in mean serum potassium was not clinically significant; a 
fall in serum potassium was seen in 32 (78%) patients. However, 
none of the patients had severe hypokalemia (serum potassium 
levels <2.5 mEq/L) and only three patients had asymptomatic 
hypokalemia (serum potassium levels <3.5 mEq/L). Correlation 
of change in serum potassium levels with various parameters is 
depicted in Table 3.
As shown in Table 3, salbutamol-induced decrease in serum 
potassium concentration was significantly correlated to the 
number of nebulizations (r=−0.49, p<0.05; Fig. 1) and also 
duration of repeated nebulizations (r=−0.52, p<0.05; Fig. 2), 
i.e., as the number and duration of salbutamol nebulizations 
increased, negative change in serum potassium levels increased. 
Furthermore, more severe the episode of acute wheeze, i.e., more 
the PAS at the onset, greater was the change in serum potassium 
levels (r=−0.43, p<0.05) (probably because they required greater 
number and duration of repeated salbutamol nebulizations). 
Change in heart rate was also significantly correlated to change in 
serum potassium levels (r=−0.37, p<0.05). Age, however, had no 
bearing on change in potassium levels (p=0.66). The mean change 
after various number of repeated nebulizations is shown in Fig. 3.
The mean QTc at the end of 1 h and 3 h of repeated nebulizations 
was 0.41±0.02 s (ranged from 0.37 to 0.44 s) and 0.43±0.01 s 
(ranged from 0.42 to 0.44 s), respectively. The mean increase 
in QTc at 3 h was 0.004±0.01 (p value: 0.137, paired t-test). No 
correlation was found between change in QTc at 3 h of repeated 
nebulizations and number/duration of salbutamol nebulizations 
and change in heart rate or change in serum potassium levels. 
However, a significant correlation was found between the severity 
of acute wheeze at onset and change in QTc at 3 h (r=0.564, 
p<0.05) as shown in Table 4.
DISCUSSION
We conducted this study because though children are offered 
repeated salbutamol nebulizations for acute wheeze, there are 
Table 3: Correlation of change in serum potassium levels with 
various parameters
Parameters Change in potassium level
Pearson correlation (r) p value
Number of repeated 
nebulizations received
−0.49 0.001
Duration of repeated 
nebulizations (min)
−0.52 0.001
Change in heart rate −0.37 0.017
Severity of acute wheeze 
(PAS at the onset)
−0.43 0.005
Age (years) 0.07 0.675
PAS: Pediatric asthma score
Figure 1: Correlation between change in serum potassium levels and 
number of nebulizations
Figure 2: Correlation between change in serum potassium levels and 
duration of nebulizations
Figure 3: Variation in mean change in serum potassium levels with 
various number of nebulizations
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only a few studies on change in serum potassium levels in them. 
Furthermore, most of the studies done in the past have studied 
children receiving up to three repeated salbutamol nebulizations, 
whereas many a times, children with acute wheeze require a 
larger number of repeated salbutamol nebulizations for the 
alleviation of symptoms [11,12]. In this study, the change in 
serum potassium levels was studied in children requiring repeated 
salbutamol nebulizations ranging from 3 to 6 over a period of 
up to 90–230 min. Furthermore, there are only a few studies 
on beta2-agonist-induced QTc prolongation on ECG in such 
children [16-18]. The severity of wheeze in these children was 
objectively assessed by doing a PAS at presentation [19].
In the demographic characteristics, the mean age of the study 
population was 3.1±3.0 (mean±SD) (years). Of the 41 children 
studied, 58.5% were boys and 41.5% were girls. The gender 
distribution and mean age in our study were slightly different 
from the one done by Singhi et al. [11] where they studied 46 
children in the age group of 10 months–12 years, of which 
41 (89%) were male and only 5 (11%) were females. The mean 
age of children in their study was 7.5±1.5 (mean±SD) (years). 
Hung et al. [12] studied 17 children with acute asthma in the age 
group of 3–14 years, 12 (70.5%) were male and 5 (29.5%) were 
females. The mean age of children in their study was 7.82±2.90 
(mean±SD) (years). Although, in our study, the number of male 
children presenting with acute wheeze was more as compared 
to females, the gender difference was less as compared to other 
studies [11,12].
It was seen that, at the end of repeated salbutamol nebulizations, 
there was a significant increase in mean heart rate (15.6±5.2, 
p<0.05). This increase in heart rate is probably due to cardiac 
sympathetic stimulation by salbutamol. Even though alleviation 
of respiratory symptoms with therapy may actually decrease 
endogenous cardiac sympathetic activity and reduce tachycardia, 
this effect is probably overpowered by sympathetic stimulation 
of the heart by the exogenously administered salbutamol, as was 
evident in our study. In the study done by Hung et al., there was 
no significant increase in heart rate after salbutamol nebulization. 
In their study, the mean baseline heart rate was 129.58±9.04, and 
after single dose of 0.125 mg/kg of nebulized salbutamol, the 
same was 130.16±8.27 (p>0.05) [12]. This is in contrast to our 
study and is probably due to the difference in protocol. However, 
in a retrospective study done by Phumeetham et al. in children 
who had used high-dose continuous salbutamol nebulization 
(75–150 mg/h), the increment in heart rate versus initial heart 
rate (%) was 12.6±10.8 which was statistically significant 
(p<0.05) [20]. Respiratory rate decreased significantly with a 
mean fall of 7.7±4.0, p<0.05, after therapeutic intervention with 
repeated salbutamol nebulizations. In the study done by Hung 
et al., fall in respiratory rate was 7.7±3.78, p<0.01. This was after 
a single dose of 0.125 mg/kg of nebulized salbutamol [12].
In our study, the mean serum potassium level at the onset 
of nebulizations and at the end of repeated nebulizations was 
4.3±0.5 and 4.0±0.5, respectively. The mean fall in potassium 
level post-repeated nebulizations was 0.3±0.4 which was 
statistically significant, p<0.05. The results yielded by our study 
were comparable to the study done by Singhi et al., where the 
average fall after three repeated salbutamol nebulizations given 
at 30 min interval was 0.2 mEq/L [11]. In our study, a fall in 
serum potassium was noticed in 32 patients (78%). However, 
none of our patients had severe hypokalemia (serum potassium 
<2.5 mRq/L) and only 3 (7%) had hypokalemia (serum potassium 
<3.5 mEq/L). This was in contrast to the study done by Singhi 
et al., where 39% of patients had hypokalemia (serum potassium 
<3.5 mEq/L) and the decrease in potassium level was found more 
often in children who had received oral salbutamol for a week or 
more before nebulization therapy.
In our study, we had excluded those children with acute 
wheeze who had taken prior oral salbutamol (as brought out 
in exclusion criteria). Our results were comparable to another 
retrospective observational study done by Hartman et al. on 279 
children with acute asthma who were treated with salbutamol 
nebulizations. In their study, it was seen that only 4.7% of the 
children had clinically significant hypokalemia (<3.0 mEq/L) 
and that too was mostly seen in those children who had 
received a cumulative dose of 0.6 (0.39–0.76 mg/Kg/h) (median 
displayed with interquartile range) during management of acute 
asthma [21]. Phumeetham et al. in their retrospective study on 
children who had received high-dose salbutamol nebulization 
(75–150 mg/h) over a mean duration of 22.3 h found that 
hypokalemia (serum potassium <3 mEq/L) had occurred in 5 of 
33 patients (15.2%) who had serum electrolytes measured while 
on continuous salbutamol treatment [20].
Of 41 children in our study, 21 children required three repeated 
salbutamol nebulizations, 7 required four repetitions, 10 required 
five repetitions, and 3 required six repeated nebulizations. 
Salbutamol-induced decrease in serum potassium levels was 
found to be significantly correlated to a number of nebulizations 
(r=−0.49, p<0.05). The mean change varied with number of 
nebulizations; it was 0.06 mEq/L after three, 0.44 mEq/L after 
four, 0.66 mEq/L after five, and 0.43 mEq/L after six nebulizations, 
respectively. Thus, the fall is clinically insignificant after three 
repeated nebulizations but becomes significant after four or 
more nebulizations. In a retrospective observational study done 
Table 4: Correlation of change in QTc (at 3 h) with various 
parameters
Parameters Change in QTc
Pearson correlation (r) p value
Number of repeated 
nebulizations received
0.19 0.545
Duration of repeated 
nebulizations (min)
0.16 0.598
Change in heart rate −0.17 0.588
Change in serum potassium 
levels
0.15 0.636
Severity of acute wheeze  
(PAS at the onset)
0.56 0.045
PAS: Pediatric asthma score
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by Hartman et al., children who were most frequently nebulized 
(>2–3 times/h for >2–3 h) showed a significantly higher incidence 
of hypokalemia (71.0%, n=31) [21]. However, more studies need 
to be done to study the change in serum potassium levels with >3 
repeated salbutamol nebulizations.
In our study, salbutamol-induced change in potassium was 
significantly correlated to change (increase) in heart rate (r=−0.37, 
p<0.05) and severity of PAS at the onset (r=−0.43, p<0.05). 
Children with more severe episodes may also be having increased 
circulating adrenaline which can further stimulate Na-K-ATPase 
pumps and can lower potassium levels in additive manner with 
salbutamol [22].
We studied QTc interval of patients while on repeated 
salbutamol nebulizations. ECG was done at 1 h of repeated 
nebulizations for all children and at 3 h for 13 children because 
they required repeated nebulizations up to 3–4 h. None of our 
patients were found to have any arrhythmia. We studied QTc 
objectively as there have been case reports of a prolonged QT 
interval which is a marker for the likelihood of ventricular 
tachyarrhythmia such as torsades de pointes and also a risk factor 
for sudden death [17,18].
In our study, mean QTc at 1 h and 3 h of repeated nebulizations 
was 0.41±0.02 (s) and 0.43±0.01 (s), respectively. There was no 
significant change in mean QTc in ECGs taken at 3 h (0.004 s, 
p=0.137). However, a significant correlation was found between 
PAS at the onset and change in QTc at 3 h (r=0.564, p<0.05). The 
QTc findings of our study were in contrast to a study done by 
Khalilian et al. who found that there was a statistically significant 
difference in QTc before and after three repeated salbutamol 
nebulizations administered at 20 min interval. In their study, 
mean increase in QTc in the group receiving three repeated 
nebulizations at a dose of 0.15 mg/kg/dose was 0.02±0.01 (s), and 
in the group receiving nebulizations at a dose of 0.1 mg/kg/dose, 
it was 0.01±0.01 (s); both of which were statistically significant 
(p<0.05) [14]. From our study, it appears that repeated salbutamol 
nebulizations cause no significant QTc changes. However, 
in children with higher severity scores at the onset, cardiac 
monitoring is warranted if they continue to receive repeated 
salbutamol nebulizations up to 3–4 h.
The strength of our study is that we have studied the effect 
of repeated salbutamol nebulizations (three or more) on serum 
potassium levels, unlike studies done in the past who have 
mostly studied this effect for maximum up to three repeated 
salbutamol nebulizations or after a single large dose of nebulized 
salbutamol. Furthermore, we excluded those children who were 
on any prior systemic medications that could affect serum 
potassium levels. The limitation of our study is that we did not 
include those children who also required other medications 
such as ipratropium, prednisolone, and aminophylline during 
the initial acute phase, which could further activate cAMP-
dependent Na+/K+ ATPase, which in turn might accentuate 
symptomatic hypokalemia. Hence, the effect of repeated 
salbutamol nebulizations on serum potassium while the child 
is on multiple drugs could not be studied. However, practically, 
we often require a combination of these drugs during the 
management of acute severe asthma.
CONCLUSION
Repeated salbutamol nebulizations, in children aged 6 months 
to 12 years, are associated with an increase in heart rate and 
a decrease in respiratory rate. A statistically significant mean 
fall in serum potassium level was observed. The study also 
revealed that the fall in potassium levels was more in those 
children who received >3 repeated salbutamol nebulizations. 
However, there were no arrhythmias or QTc abnormalities seen. 
We conclude that serum potassium levels should be monitored 
in children receiving repeated salbutamol nebulizations for 
acute wheeze.
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